Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour

Authors

Abdullah Ladha, Aga Khan University
Mohammad Usman Shaikh, Aga Khan University

Document Type

Article

Department

Pathology and Microbiology

Abstract

In this study, the response of Imitanib Mesylate in patients with Gastro-intestinal stromal cell tumour (GIST) was assessed. GIST results from a mutation in one of the receptor protein tyrosine kinases. Imitanib Mesylate, a tyrosine kinase inhibitor, has emerged as a promising new treatment for GISTs. Total 16 cases were reviewed. Diagnosis was based on biopsy and immunohistochemistry. Response assessment was done using CT scans, at a median duration of 4 months. The median age of the patients was 52 years, Majority were male (n=14). Most common presenting complaint was abdominal pain (n=7). Commonest primary site was stomach (n=7), Liver was the most common organ involved in metastasis (n=8). All patients received Imitanib 400 mg orally, once a day. No mortality was reported during median follow up time of 28 months on Imitanib. There was also either radiological remission (n=5) or response (n=5), in about half of the patients without any serious side effects.

Publication (Name of Journal)

Journal of the Pakistan Medical Association

Recommended Citation

Ladha, A., Shaikh, M. (2008). Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour. Journal of the Pakistan Medical Association, 58(12), 696-7.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/44